X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The objective of this pilot study is to assess microcatheter-based delivery of CypCaps in the pancreatic arterial system. volume of dose, number of CypCaps, and treatment location will be evaluated using imaging and histology.
Lead Product(s): CypCaps,Ifosfamide
Therapeutic Area: Oncology Product Name: CypCaps
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CBSET
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
The study has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of its CypCaps plus ifosfamide pancreatic cancer therapy for the treatment of malignant ascites.
Lead Product(s): CypCaps,Ifosfamide
Therapeutic Area: Oncology Product Name: CypCaps
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Heidelberg Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
CypCaps showed, no evidence of toxicity in this animal study in any of the parameters examined and that the study confirms previous data that the capsule material is inert.
Lead Product(s): Encapsulated Live Cells Ifosamide Prodrug
Therapeutic Area: Oncology Product Name: CypCaps
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
CypCaps are genetically engineered human cells, specifically engineered to treat unresectable pancreatic cancer, and encapsulated using PharmaCyte's Cell-in-a-Box technology.
Lead Product(s): Encapsulated Live Cells Converting Ifosamide
Therapeutic Area: Oncology Product Name: CypCaps
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Details:
The significance of this timepoint is that CypCaps (encapsulated live cells converting ifosamide) has now demonstrated that it has a shelf life of at least 24 months when stored at -80 degree, also maintain viability, enzymatic activity and cell potency.
Lead Product(s): Encapsulated Live Cells Ifosamide Prodrug
Therapeutic Area: Oncology Product Name: CypCaps
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active (Ifosfamide) or “cancer-killing” form.
Lead Product(s): Encapsulated Live Cells Converting Ifosamide
Therapeutic Area: Oncology Product Name: CypCaps
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
Study demonstrates that the CypCap capsule material is not in any way toxic to encapsulated live cells, the material is bio-inert and used to treat locally advanced, inoperable pancreatic cancer.
Lead Product(s): Encapsulated Live Cells Converting Ifosamide
Therapeutic Area: Oncology Product Name: CypCaps
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2022
Details:
PharmaCyte uses for locally advanced, inoperable pancreatic cancer—Cell-in-a-Box (CypCaps™) combined with the cancer killing prodrug ifosfamide—can also delay the rate of production and accumulation of malignant ascites.
Lead Product(s): Encapsulated Live Cells Converting Ifosamide
Therapeutic Area: Oncology Product Name: CypCaps
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
Details:
Analysis after 18 months in storage at -80oC, the unfrozen CypCaps product passed all the specified tests, including cell viability, enzyme activity, cell potency, pH, label check, capsule appearance and integrity.
Lead Product(s): CypCaps,Ifosfamide
Therapeutic Area: Oncology Product Name: CypCaps
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
PharmaCyte is positioned to immediately move into a fully funded clinical trial in LAPC should the FDA lift the clinical hold.
Lead Product(s): Encapsulated Live Cells,Ifosfamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 25, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
